LARVOL is pleased to present a moderated discussion with top oncologists following AACR's Annual Meeting 2021. In the video below, Dr. Binod Dhakal, Dr. Carl Ola Landgren, and Kinisha Gala discuss the practice-changing impact of AACR presentations in hematological malignancies.
On April 19, 2021 LARVOL hosted an oncology panel discussion on the top hematologic clinical trial abstracts presented during the American Association for Cancer Research (AACR) Annual Meeting 2021, held on April 10-15, 2021. LARVOL's Kinisha Gala moderated the discussion between hematology KOLs - Dr. Binod Dhakal from Medical College of Wisconsin and Dr. Carl Ola Landgren from the University of Miami.
The discussion covered AACR abstract #CT001 CHRONOS-3: Randomized Phase III study of copanlisib plus rituximab vs rituximab/placebo in relapsed indolent non-Hodgkin lymphoma (iNHL), AACR abstract # CT036 Axicabtagene ciloleucel (axi-cel) product attributes and immune biomarkers associated with clinical outcomes in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5, and AACR abstract # CT023 PATHFINDER: Interim analysis of avapritinib (ava) in patients (pts) with Advanced Systemic Mastocytosis (AdvSM).
This discussion reviewed the options for patients with relapsed indolent-non-Hodgkin lymphoma and addressed new therapeutic options for rare hematologic malignancies.
Watch this video for the full discussion:
Our AACR Panel Series covered five therapeutic areas including hematological malignancies. Click below to read more about them and watch their video analysis.